CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
出版年份 2023 全文链接
标题
CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
作者
关键词
-
出版物
CYTOKINE & GROWTH FACTOR REVIEWS
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-10-06
DOI
10.1016/j.cytogfr.2023.10.001
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.
- (2023) Antonio Llombart-Cussac et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
- (2023) Kevin Kalinsky et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
- (2023) Mariusz Shrestha et al. Oncogenesis
- Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study
- (2022) Massimo Cristofanilli et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
- (2022) Melanie Royce et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
- (2022) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
- (2022) Marta Palafox et al. Nature Communications
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
- (2022) Stephen R D Johnston et al. LANCET ONCOLOGY
- Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
- (2022) Masakazu Toi et al. ONCOLOGIST
- The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
- (2021) Andrea C. Chaikovsky et al. NATURE
- CRL4AMBRA1 is a master regulator of D-type cyclins
- (2021) Daniele Simoneschi et al. NATURE
- CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory
- (2021) Emily J Lelliott et al. Cancer Discovery
- Inhibition of CDK4/6 promotes CD8 T-cell memory formation
- (2021) Max Heckler et al. Cancer Discovery
- Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
- (2021) D.J. Slamon et al. ANNALS OF ONCOLOGY
- Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
- (2021) Lindsey R. Pack et al. Nature Communications
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
- (2021) Yen-Shen Lu et al. CLINICAL CANCER RESEARCH
- Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation
- (2021) Ines H. Kaltheuner et al. Nature Communications
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
- (2020) Laura M Spring et al. LANCET
- c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
- (2020) Wenfei Ji et al. Cell Death & Disease
- Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells
- (2020) Reeja S. Maskey et al. CELL CYCLE
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Can CDK4/6 inhibitors cause fatal lung injury?
- (2019) Khalid A. Jazieh et al. Expert Review of Anticancer Therapy
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
- (2017) Emily M. Cousins et al. MOLECULAR CANCER RESEARCH
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival
- (2017) Haizhen Wang et al. NATURE
- ATRX is a regulator of therapy induced senescence in human cells
- (2017) Marta Kovatcheva et al. Nature Communications
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
- (2015) Marta Kovatcheva et al. Oncotarget
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started